Healthcare Industry News: amphotericin B
News Release - August 14, 2007
BDSI Names David Blum, M.D. Vice President of Medical Affairs and Clinical ResearchDr. Blum Joins BDSI from GlaxoSmithKline
MORRISVILLE, N.C.--(HSMN NewsFeed)--BioDelivery Sciences International, Inc. (Nasdaq: BDSI ) has hired David Blum, M.D. as Vice President of Medical Affairs and Clinical Research, a newly created position, effective September 4, 2007. In this role, Dr. Blum is responsible for the design, conduct, analysis and reporting of all clinical research studies required to support additional claims for the Company's Phase III BEMA(TM) Fentanyl product and the development of other products in the Company's portfolio, including BEMA LA and Bioral® amphotericin B.
Dr. Andrew Finn, Executive Vice President of Product Development at BDSI commented, "We are honored and delighted to have Dr. Blum join our development group. He is an experienced clinician and researcher who has contributed to the development of a number of products during his industry career, including, but not limited to, an anticonvulsant for diabetic neuropathy and a COX-2 inhibitor for arthritis. We believe his experience will be particularly valuable to BDSI as we seek to complete the development of our flagship BEMA Fentanyl product and enter Phase II and III development with our BEMA LA product for broader pain indications. Dr. Blum's hiring is evidence of the commitment BDSI has in building a solid development infrastructure and, in particular, our aggressive pursuit of our pain products."
About BioDelivery Sciences International
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company that is focused on developing innovative products to treat acute conditions such as pain. The company utilizes its owned and licensed patented drug delivery technologies to develop, partner and commercialize, clinically-significant new products using proven therapeutics. BDSI's pain franchise currently consists of two products in development utilizing the company's patented BEMA(TM) oral adhesive disc technology: BEMA(TM) Fentanyl, a treatment for "breakthrough" cancer pain, and BEMA(TM) LA, a second analgesic with a target indication of the treatment of moderate to severe pain. The company is also working with both its BEMA(TM) technology and its patented Bioral® nanocochleate technology on products targeted at other acute treatment opportunities such as insomnia, nausea and vomiting, and infections. The company's headquarters are located in Morrisville, North Carolina and its principal laboratory is located in Newark, New Jersey. For more information please visit www.bdsinternational.com.
Note: Except for the historical information contained herein, this press release contains, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Such statement may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects", "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, the application of funds, the performance of new hires, or the timing for completion and results of scheduled or additional clinical trials and FDA review of the Company's formulations and products, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). Peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such sales levels will be achieved, if at all.
Source: BioDelivery Sciences International
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.